GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » 3-Year EPS without NRI Growth Rate
中文

Hansoh Pharmaceutical Group Co (HKSE:03692) 3-Year EPS without NRI Growth Rate : -2.50% (As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co 3-Year EPS without NRI Growth Rate?

Hansoh Pharmaceutical Group Co's EPS without NRI for the six months ended in Jun. 2023 was HK$0.24.

During the past 12 months, Hansoh Pharmaceutical Group Co's average EPS without NRI Growth Rate was -11.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was -2.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 8.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Hansoh Pharmaceutical Group Co was 22.00% per year. The lowest was -2.50% per year. And the median was 14.20% per year.


Competitive Comparison of Hansoh Pharmaceutical Group Co's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansoh Pharmaceutical Group Co's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's 3-Year EPS without NRI Growth Rate falls into.



Hansoh Pharmaceutical Group Co 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Hansoh Pharmaceutical Group Co  (HKSE:03692) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Hansoh Pharmaceutical Group Co 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Traded in Other Exchanges
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines